Apricus Biosciences' (APRI) main drug is Vitaros; a topical treatment for erectile dysfunction (ED) that has found partners in many countries but is waiting for Abbott to start Canadian sales and get ...
* Co has lost $65 mln in market cap since Feb rejection of Vitaros (Adds details on options, background, shares) April 16 (Reuters) - Apricus Biosciences Inc said on Monday it was considering options ...
SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...
SAN DIEGO, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group ("Neopharm" ...
SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), announced today that Apricus signed an exclusive license ...
An Israeli pharmaceutical and consumer health products company has agreed to sell Vitaros, an erectile dysfunction cream made by Apricus Biosciences, in that country and the Palestinian Territories, ...
SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of ...
Apricus Biosciences has received European approval to market alprostadil 0.3% topical cream (Vitaros) for the treatment of erectile dysfunction (ED), the company announced today. Vitaros is a ...
A woman inadvertently put erectile dysfunction cream into her eye after a mix-up over two medications with very similar names. The patient, whose name and age are unknown, ended up with redness, ...
That pharmacist might want to get his or her vision checked. A pharmacist in Glasgow, Scotland, misread a woman’s prescription for VitA-POS, a lubricant for severe dry eye and corneal erosions, as ...
(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results